Pilot trial of memantine in primary progressive aphasia

Alzheimer Disease and Associated Disorders

Volumn 24, Issue 3, 2010, Pages 308-

  Johnson, Nancy A ^a   Rademaker, Alfred ^a   Weintraub, Sandra ^a   Gitelman, Darren ^a   Wienecke, Christina ^b   Mesulam, Marsel ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Cognitive Neurology and AD Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; GALANTAMINE; MEMANTINE; PLACEBO;

ABSENCE OF SIDE EFFECTS; APHASIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; LETTER; PILOT STUDY; PRIMARY PROGRESSIVE APHASIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

APHASIA, PRIMARY PROGRESSIVE; DISEASE PROGRESSION; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; HUMANS; MEMANTINE; TREATMENT OUTCOME;

EID: 77956419130     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3181cf468d     Document Type: Letter

References (6)

1. Mesulam MM. Primary progressive aphasia- a language-based dementia. N Engl J Med. 2003;349:1535-1542.
2. Reed D, Johnson N, Thompson C, et al. A clinical trial of bromocriptine for treatment of primary progressive aphasia. Ann Neurol. 2004;56:750.
3. Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25:178-185.
4. Boxer A, Lipton AM, Womack K, et al. An open-label study of Memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009;23:211-217.
5. Mesulam MM, Wieneke C, Rogalski E, et al. Quantitative template for subtyping primary progressive aphasia. Arch Neurol. 2009;66:1545-1551.
6. Kertesz A. Western Aphasia Battery (WAB). San Antonio, Texas: The Psychological Corporation; 1982.